Why Inozyme Pharma (INZY) Shares Are Trading Higher Today

Inozyme Pharma Inc (NASDAQ: INZY) announced topline pharmacokinetic (PK), pharmacodynamic (PD), and safety data from the ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency (PXE). Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) was observed, and an encouraging patient-reported outcome data in all dose cohorts in the ENPP1 …

Read More »